Feline kidney cells were transfected with a vector overexpressing cytochrome P450 2B1 ( CYP2B1 ) . Transfected cells acquired a new specific biochemical activity, which could be demonstrated by a rapid CYP2B1 detection assay and showed selective sensitivity to the antitumorigenic prodrug ifosfamide ( IFO ) . Further, the cell -killing effect was also mediated on nonmodified cells like feline kidney cells, mouse lymphoma, and human pancreatic cells in the vicinity of the CYP2B1 -expressing cells due to the diffusible nature of the activated IFO metabolites. One of these, phosphoramide mustard, causes interstrand DNA cross -linking and it has been thought that the inability to repair this damage results in apoptosis. Surprisingly, our results clearly demonstrate a necrotic mechanism of IFO -induced cell death. This may have important implications for the activation of the immune system during CYP2B1 / IFO suicide gene therapy of cancer. Cancer Gene Therapy ( 2001 ) 8, 220 ± 230
T he principle underlying many chemotherapeutic and radiological tumor treatments is the chemical modification of DNA leading to cell death on subsequent cell division. Tumor cells, in general, divide more frequently than normal somatic cells, allowing the effects of the treatment to be predominantly targeted to such cells. However, a variety of other cells, such as those of the hematopoietic system, are also actively dividing and are thus also drastically effected by such treatments, limiting effective dosing, and thus tumor response.
The oxazaphosphorine ifosfamide (IFO ) is an inactive prodrug that is delivered systemically and becomes activated predominantly in the liver by enzymes belonging to the cytochrome P450 family. Although this family has many members, only few are able to activate IFO. In rats, the most frequently investigated model, the isoform 2B1 (CYP2B1) has been shown to catalyze conversion to the activated form of IFO, which is unstable and spontaneously decays to acrolein and isophosphoramide mustard. 1 Targeting of the conversion of IFO into its active metabolites directly to the tumor will reduce the systemic toxicity of the system, while maintaining a high local toxicity at the tumor site. Using genetically modified cells expressing the CYP2B1 gene, it could be shown that activated freely diffusible metabolites of IFO have an effect on neighboring nontransduced cells. 2 Unlike other commonly used suicide -prodrug systems such as herpes simplex virus ( HSV ) thymidine kinase ( tk ) /ganciclovir, the bystander effect could be shown to be independent of gap junctions. Thus, cytochrome P450s may be more potent than other systems for gene -directed drug activation. A further advantage to the use of cytochrome P450 enzymes is that they are expected to be less immunogenic than suicide enzymes such as the HSV tk and thus should allow longterm drug activation. In former studies, it was demonstrated that the cytochrome P450/ oxazaphosphorine system mediates a suicide and a bystander effect both in vitro and in vivo. 2, 3 To address this point we introduced a CYP2B1 expression vector 4 into feline kidney cells. 5 Using a biochemical assay, 6 it was possible to demonstrate CYP2B1 activity in stably transfected feline kidney cells. As a result of this CYP2B1 activity, IFO in the culture medium became cytotoxic and led to cell death. In the studies reported here, it could be shown that the bystander effect is able to reduce the growth of mouse lymphoma 7 and human pancreatic carcinoma cells 8 and could be correlated with the number of CYP2B1 -expressing cells.
Because it is unlikely that a sufficient number of tumor cells could be eliminated directly by the bystander effect to result in cure in vivo, further mechanisms such as an activation of the immune system, would be advantageous. Phosphoramide mustard, the active product of IFO, is known to cause interstrand cross -links suggesting that, as a result of this DNA damage, cells not able to repair will be eliminated by apoptosis. Such a mechanism will only lead to a limited if any release of antigenic fragments, thus reducing the likelihood of a stimulation of the immune system. However, with its associated cell frag-mentation, it might be therapeutically advantageous if cell killing resulted in necrosis. 9 To resolve this issue we investigated the exact mechanism of cell killing by activated IFO.
Most of the investigations designed to reveal apoptosis have used TUNEL staining or DNA laddering assays. The TUNEL procedure was initially thought to reveal apoptotic cells but it is now known that it also detects necrotic cells. 10 ± 13 Detection of DNA fragmentation is a qualitative method but does not allow investigations on a single -cell level. Therefore, we chose transmission electron microscopy for unambiguous qualitative investigations at the single cell level and combined it with fluorescenceactivated cell sorting (FACS ) after annexin V / propidium iodide staining of cells. Surprisingly, using both annexin V / propidium iodide staining as well as electron microscopy we were unable to find the typical features of apoptosis but rather found changes in the cellular membrane and the intracellular structure, which strongly argue for a necrotic cell death. Our data confirm that the combination of CYP2B1 with IFO is a good choice for mediating a diffusible suicide bystander effect on heterologous cells and, in addition, for the first time demonstrate clear evidence for a necrotic cell death, which should allow the subsequent activation of the immune system. These findings increase the potential value of this suicide system as a therapeutic principle.
MATERIALS AND METHODS

Cell culture
CRFK cells, an epithelial feline kidney cell line, 5 and PANC1, a human ductal adenocarcinoma cell line, 8 were cultured at 378C in Dulbecco's modified Eagle's medium with glutamax (Gibco BRL ) supplemented with 10% fetal calf serum (FCS ) in 5% CO 2 . Stably transfected clones ( CKlx2, C8III -1, PANCgfp1 ) were cultured in medium containing additionally 400 g/ mL G418. A20 Balb /c B -cell lymphoma suspension cells 7 were cultured in RPMI 1640 medium with 0.05 mM 2-mercaptoethanol and 10% FCS.
Transfection
PANC1 cells were transfected with the enhanced green fluorescent protein (EGFP ) expression plasmid, pCMVegfp, 14 using the calcium phosphate transfection method (Pharmacia ) according to the manufacturer's instructions. Briefly, the day before transfection, 5Â10 5 PANC1 cells were seeded into a 3-cm dish. Three hours before transfection the medium was removed, cells washed with phosphate -buffered saline (PBS ), and new medium added. For the transfection, 10 g of plasmid DNA was used. Transfected PANC1 cells 8 were selected in media containing 400 g/ mL G418 and after 2 weeks EGFP -expressing G418 resistant clones were isolated. The clone used in this study is called PANCgfp1.
For stable expression of -galactosidase in CrFK cells, the retroviral vector pLXlacZ with the lacZ gene under the control of the murine leukemia virus (MLV ) promoter was transfected and selected as described above. The cell line used in this study is called CKlx2.
For CYP2B1 expression CrFK cells were transfected with the eucaryotic expression plasmid pc3/ 2B1. 4 G418 resistant clones were isolated and analyzed. The clone that was used in this study is called C8III -1.
Detection of CYP2B1 activity
CrFK and C8III -1 cells were investigated as previously described 4 according to a modified protocol for the specific detection of CYP2B1 and CYP1A1 activity in cell supernatant. 6 Functional CYP2B1 dealkylates 7 -pentoxyresorufin to resorufin, which fluoresces at 590 nm when excited at 530 nm.
Cytotoxicity assay
In a 3 -cm dish, 4Â10 4 cells were seeded in 2 mL of medium. The next day, IFO was added to final concentrations from 0 to 5 mM. After six additional days the medium was removed, the cells washed with PBS, and either stained or counted.
For Giemsa staining the cell layer was fixed with acetic acid /methanol (1:3 ) for 30 minutes. The fixation fluid was removed, the cells air dried, and warm Giemsa /water ( 1:8 ) added for 1 hour. The cells were rinsed with water and air dried.
For the quantitative analysis, cells were washed with PBS, trypsinized, and an aliquot mixed with the same volume of 0.4% trypan blue solution. After a 1-minute incubation period, the dead cells, showing blue staining, were excluded and living cells counted. The relative cell number was calculated as the ratio between cells with and without IFO treatment.
Cocultivation assays
Cocultivation with CKlx2 cells. CKlx2 cells (2Â10 4 ) were seeded together with the same number of either C8III -1 or CrFK cells, respectively. The next day, the cells were treated with IFO to final concentrations of 0 to 5 mM. After six additional days the cell layer was washed twice with PBS and fixed with 2% paraformaldyhyde (Sigma) in PBS for 20 minutes. After fixation, the cell layer was rinsed twice with PBS, covered with 1 mL staining solution (0.4 mM K 3 Fe (CN ) 6 , 0.8 mM K 4 Fe( CN ) 6 CrFK wt, PANCgfp1 ) were seeded in a 6 -cm dish. The next day the cells were treated with IFO to a final concentration of 0.5 mM. After six additional days, an aliquot of each group was stained with trypan blue as described above and living cells counted. The remainder of the cells in each dish was used for FACS analyses.
FACS analysis
For the detection of EGFP expression in the pancreatic cells, the trypsinized cells were diluted in PBS supplemented with 5% FCS. FACS analyses were carried out on a FACScalibur (Becton -Dickinson, Heidelberg, Germany ) configured for analysis of fluorescein isothiocyanate and trimethylrhodamine isothiocyanate fluorescence as described elsewhere.
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Annexin V / propidium iodide labelling
Into a 3-cm dish, 1Â10 5 cells were seeded and the next day treated with either 100 M 4 -hydroperoxy -IFO ( 4OOH -IFO ) , 0.5 mM IFO or 1 M staurosporine. Four days later the cells were trypsinized, washed once with PBS, and once with 1Â binding buffer (Trevigen) . After centrifugation at 250Âg for 5 minutes the cell pellet was resuspended in 80 -L staining solution, which was prepared according to the manufacturer's ( Trevigen ) instructions. After a 15 -minute incubation period at room temperature, the cells were mixed with 500 L 1Â binding buffer and used for FACS analysis.
Electron microscopy
Into a 10 -cm dish, 5Â10 6 cells were seeded, treated with IFO or 4OOH -IFO the next day, and after three days trypsinized, combined with cells pelleted by centrifugation from the cell culture medium, fixed for 2 to 4 hours in 2.5% glutaraldehyde /0.1 mM Sorenson's phosphate buffer pH 7.38, and later washed in Sorenson's phosphate buffer. After each of the following steps, the cells were pelleted by centrifugation at 250Âg for 5 minutes. The cell pellet was incubated for 90 minutes in 1% OsO 4 /0.1 mM Sorenson's phosphate buffer, washed three times in H 2 O, and dehydrated using a standard alcohol dehydration procedure. For embedding of the cells, an EPON (47.8% glycid ether, 28.7% methylnadic anhydride, 21.5% 2 -dodecenylsuccinate, 1.96% 2,4,6 -tris -( dimethylamino-methyl ) phenol ) -based method was used. Cells were incubated for 10 minutes in 1,2 -propylene -oxide, 1 hour in propylene oxide /EPON ( 1:1 ), and 1 hour with propylene oxide / EPON ( 1:3 ) . After EPON ( 100% ) treatment overnight the supernatant was replaced by new EPON and polymerized at 608C for 48 hours. Ultrathin sections (60 ±70 nm ) were cut by using a Reichert Ultracut S and transferred onto a copper mesh (200 mesh, 3.05 mm ) . Sections on the mesh were contrasted by laying the mesh 7 minutes upside down on a uranyl acetate solution (2% in methanol ) and washing in water. The dried meshes were transferred for 5.5 minutes into a lead citrate solution (120 mM sodium citrate, 80 mM lead nitrate ), washed in water, and air dried overnight. For further analysis, a transmission electron microscope ( EM900, Zeiss ) was used. As a control untreated cells or cells, which were treated 16 hours with staurosporine, were analyzed.
RESULTS
CYP2B1 -expressing cells show specific biochemical activity
CrFK and C8III -1 cells ( expressing CYP2B1 from the transfected construct ) were seeded at different densities and overlaid with medium containing 7 -pentoxyresorufin. The CYP2B1 -specific dealkylating activity converts 7 -pentoxyresorufin to resorufin, which fluoresces at 590 nm, when excited at 530 nm. 6 The total amount of resorufin in each cell population was calculated using a standard curve. CYP2B1 expression in CrFK cells results in enhanced sensitivity toward IFO Both the CYP2B1-expressing C8III -1 cells and parental CrFK cells were treated with different concentrations of IFO ( 0± 5 mM ). In the absence of IFO, both cell types grew to confluence (Fig 1A; 0 mM IFO ) . However, clear differences in cell density were already visible at 0.25 mM IFO ( Fig 1A ) . The cell monolayer formed by the CYP2B1-expressing C8III -1 cells was patchy, whereas CrFK cells showed no response to 0.25 mM IFO. With increasing concentrations of IFO, the number of C8III -1 cells was further reduced. In comparison, the CrFK cells showed no obvious reduction in cell number up to 2 mM IFO. The highest concentration of IFO used (5 mM ) was cytotoxic also for non± CYP2B1 -expressing CrFK cells. This effect is presumably nonspecific and independent of CYP2B1-mediated conversion because these cells do not express endogenous enzyme.
To quantify the cytotoxic effects of IFO treatment on C8III -1 and CrFK cells, cells in a parallel experiment were not stained but counted after 1 week. To quantify the CYP2B1 specific IFO sensitivity and to calculate the IC 50 of C8III -1 cells the experiment was performed in the low -dose range of IFO (0 to 1.0 mM ) . This experiment ( Fig 1B ) showed that even the lowest dose of IFO (0.05 mM ) could reduce the growth of CYP2B1 -expressing cells by more than 50%. The suicide effect became stronger with increasing concentrations of IFO. There was no detectable cytotoxic effect on non± CYP2B1-expressing CrFK cells at concentrations below 0.5 mM (Fig 1B ) .
Bystander effect on neighboring non ± CYP2B1 -expressing cells
Equal numbers of reporter CrFK cells stably expressinggalactosidase (CKlx2) were seeded together with C8III -1 or CrFK cells. The neighboring non ± CYP2B1 -expressing cells ( CKlx2 ) can be discriminated by X -gal staining ( Fig  2 ) . In the absence of IFO treatment ( Fig 2A; 0 mM ) the CKlx2 cells grew as a mixed population with both C8III -1 or CrFK cells. Treatment with IFO, however, led to a dosedependent reduction of the CKlx2 cells when they were cocultivated with C8III -1 cells (Fig 2A, C8III -1+ CKlx2) .
The CKlx2 cells cocultivated with CrFK cells showed only a nonspecific sensitivity to IFO. Up to 0.5 mM there was nearly no reduction in cell viability as visualized by Xgal staining (Fig 2A, CrFK + CKlx2 ) . At 1 and 2 mM the number of blue cells was reduced and all cells were killed by concentrations of 5 mM.
To exclude that IFO treatment results in down -regulation of -galactosidase expression but not in cell killing, the same cells were examined microscopically (Fig 2B ) . The results confirmed that in the absence of drug ( 0 mM IFO ) the mixed population with C8III -1 or CrFK cells grew to a confluent cell monolayer. At 0.25 mM IFO, the mixed population with C8III -1 cells showed cell killing and the effect was progressively enhanced with increasing concentrations of IFO (Fig 2B, C8III -1+ CKlx2) . In contrast, the mixed population with CrFK cells showed no cell killing up to 0.5 mM IFO. At IFO concentrations greater than 1 mM a clear nonspecific cell -killing effect could be seen ( CrFK + CKlx2) .
To address the question whether the bystander effect could also be mediated to suspension cells without a direct cell ± cell contact by gap junctions, C8III -1 or CrFK cells were seeded together with nonadherent A20 mouse lymphoma cells.
A20 cells cocultivated with C8III -1 (Fig 3A ) or CrFK cells ( Fig 3B ) showed good growth when no drug was added. In the presence of 0.25 mM IFO the growth of A20 cells cocultivated with C8III -1 cells was slowed and a strong growth inhibition was visible at 0.5 mM or higher IFO concentrations ( Fig 3A ) . In contrast, when sharing the same medium with CrFK cells, there was no response to IFO concentration up to 0.5 mM (Fig 3B ) . At 1 and 2 mM the growth rate of the cell population was reduced again presumably as a result of nonspecific toxicity. Overall, these results demonstrate clearly that the bystander effect can also be transferred to nonadherent cells without a direct cell ± cell contact.
A possible strategy for a human cell /gene -based tumor therapy is to deliver CYP2B1-expressing cells to the vicinity of the tumor allowing release of activated IFO to the neighboring tumor cells. To investigate how human pancreatic tumor cells respond to activated IFO, they were cocultured with C8III -1 cells in the presence of 0.5 mM IFO. KARLE, RENNER, SALMONS, ET AL: CYTOCHROME P450/IFOSFAMIDE MEDIATED NECROSIS To discriminate between the two cell types, the human pancreatic cell line PANC1 was stably transfected with the gene for the EGFP. The EGFP -expressing pancreatic ( PANCgfp1 ) cells were then mixed with C8III -1 and CrFK cells in different ratios as shown in Figure 4B . Nontransfected CrFK cells were used in this experiment to ensure that in each experimental group 1Â10 5 PANC1 cells were seeded with 1Â10 5 CrFK or C8III -1 cells making a total cell number of 2Â10 5 cells. This was designed to avoid problems due to the seeding of different cell numbers and possible resulting influences on the overall growth rates. In a control FACS analysis, 95% of the PANC1 population carrying the EGFP gene also expressed this protein. As expected the C8III -1 and CrFK populations did not express detectable levels of EGFP ( data not shown ). In initial experiments, the effect of treatment with 0.5 mM IFO on the growth of the different cell lines was investigated. As expected, the CYP2B1-expressing C8III -1 cells were almost completely killed by IFO treatment (Fig 4A, 94% cell killing ) . However, a slight growth inhibition (around 25% ) was also observed for both PANCgfp1 and CrFK cells (Fig 4A ) when IFO was added. We can only attribute this to experimental variation and the result of nonspecific toxicity. After 5 days cocultivation, the cells were analyzed by FACS and both the total number of cells and the number of EGFP -expressing PANCgfp1 cells was calculated. Even when only 5% of the total population consisted of CYP2B1-expressing cells, effects on the survival rate of the target pancreatic tumor cells were visible (Fig 4B, 5% ) . Only around 25% of the target cells survived when a quarter of the population was made up of CYP2B1 -expressing cells. There was no significant difference in survival when higher percentages of CYP2B1- 5 of a mixed population of CrFKwt and C8III -1 cells. These dishes contained a step -wise reduced percentage ( 50%, 45%, 25%, 5%, and 0% ) of the mixed population expressing CYP2B1 ( Clone C8III -1 ) . All dishes were prepared twice. The next day, one dish of each group was supplemented with IFO, resulting in a concentration of 0.5 mM, and the other not. On the seventh day, the total cell number of each dish was calculated. Cells were trypsinized, dead cells excluded by trypan blue staining and the living cells expressing cells were used (45%, 50% ) suggesting that the remaining 25% of pancreatic tumor cells may be refractile to cell killing during the course of the experiment.
Mechanism of cell killing after treatment with active IFO
The mechanism of cell death after using a suicide system for cancer treatment may significantly influence the outcome of a treatment. To investigate the mechanisms of IFO -mediated cell death, CrFK cells were treated with the activated form of IFO, 4OOH -IFO, for 3 days. A 3-day incubation period seemed suitable because at the end of this time period pathological changes like detached or rounded cells became visible after analysis under the light microscope. In parallel, control cells were treated 16 hours with staurosporine, a potent protein kinase C inhibitor and thus an inducer of apoptosis 16 or not treated. The trypsinized cells and detached cells from the supernatant were taken together and analyzed by annexin V /propidium iodide staining. Additionally, cellular morphology and architecture was analyzed by measuring FACS forward and sideward scatter of each cell. To investigate additionally whether there are differences in cell killing dependent on the source of the active drug ( endogenous versus exogenous ), CYP2B1 -expressing CrFK cells ( C8III -1) were treated in parallel with IFO and analyzed 3 days later. Both cells treated with 4-OOH -IFO or expressing CYP2B1 and treated with IFO ( CYP2B1 /IFO ) showed an increase in the double -stained necrotic / late apoptotic cell population but not in the KARLE, RENNER, SALMONS, ET AL: CYTOCHROME P450/IFOSFAMIDE MEDIATED NECROSIS annexin V single -stained population of apoptotic cells ( Fig 5F and H ) compared to untreated CrFK cells ( Fig  5B ) . In contrast, CrFK cells, which were treated with staurosporine, showed an increase of the necrotic /late apoptotic as well as in the apoptotic population (Fig 5D ) . Forward scatter, reflecting the cell size, and the sideward scatter, measuring the degree of granularity of the cell, were both increased for CYP2B1 /IFO -and 4 -OOH -IFO ± treated cells ( Fig 5E and G ) but not in the nontreated (Fig 5A ) or staurosporine -treated samples ( Fig 5C ) . Thus, 4 -OOH -IFO ± and CYP2B1 /IFOtreated samples neither contain an apoptotic population nor do they show a cell morphology typical of apoptotic cells. This strongly suggests that 4 -OOH -IFO ± or CYP2B1 /IFO -treated cells undergo a nonapoptotic cell death. CrFK cells were also treated with only 10 M 4-OOH -IFO or incubated only for 1 or 2 days. In these cell populations fewer cells showed morphological abnormalities but the visible abnormalities also argue for a necrotic cell death (data not shown) . Thus, the necrotic CrFKwt ( A ± D ) or CYP2B1 -expressing C8III -1 cells ( E, F ) were seeded and treated with nothing ( A ) , staurosporine ( B ) , 4OOH -IFO ( C and D ) , or IFO ( E and F ) . The third day after 4OOH -IFO or IFO treatment or after a 16 -hour incubation in the presence of staurosporine, cells were trypsinized and pooled with the cells in the medium. The total cell population was prepared for transmission electron microscopy. Magnifications are indicated under the pictures ( Â3000 to Â7000 ) . The following abbreviations were used: ER, endoplasmatic reticulum; Nu, nucleus; Mt, mitochondria; Mv, microvilli; Va, vacuoles.
Cancer Gene Therapy, Vol 8, No 3, 2001 characteristics are independent of the concentration of 4OOH -IFO in the range of 10± 100 M and are induced both after intracellular and extracellular activation of IFO.
To confirm these surprising results, CrFK cells were treated as described above and analyzed by transmission electron microscopy. In most of the 4OOH -IFO ± and CYP2B1/ IFO -treated cells no pathological changes were visible. The treated cells looked similar to the untreated sample ( Fig 6A ) . Some cells differed in size and intracellular architecture, but no characteristic features of apoptosis like cell shrinking, chromatin condensation, or formation of apoptotic bodies were visible as seen after treatment with staurosporine ( Fig 6B ) . Cells with altered architecture showed an increased cell volume, sometimes a dilation of the endoplasmatic reticulum (ER ), fragmentation of the nucleus ( Nu ) , and micronucleisation (Fig 6C ± F ) . To exclude that the necrotic picture of 4OOH -IFO ± or CYP2B1/ IFO -treated CrFK cells is simply a cell type ± specific phenomenon, Vero cells were also treated and analyzed as described for the CrFK cells. In all cells showing morphological changes, 4OOH -IFO induced structural changes like cytoplasmic swelling, increased vacuole formation, and nuclear fragmentation (Fig 7C and D ) . The characteristic features of apoptosis, as seen after treatment of Vero cells with staurosporine ( Fig 7B ) , were not observed in any case. All of these features reflect the results, which were obtained previously with CrFK cells and confirm the data from FACS analysis after annexin V /propidium iodide staining.
DISCUSSION
Many of the current gene therapeutic approaches to treat cancer focus on the direct delivery of a suicide gene that is able to activate a prodrug. One not so widely used but very promising system is the activation of the antitumorigenic prodrugs cyclophosphamide or IFO by CYP2B1. 2 ± 4,17 In our study, feline kidney cells (CrFK ) were modified so that they overexpress CYP2B1. The production of functional CYP2B1 could be demonstrated by the conversion of 7 -pentoxyresorufin to the fluorescent compound resorufin. This enzymatic assay is an easy alternative to the detection of CYP2B1 by Western blot and has the additional advantage that detection is rapid and provides a reliable method for the measurement of functional CYP2B1. 6 The IFO -activating activity was also tested in a biological assay. CYP2B1 -expressing CrFK cells were compared with wild -type CrFK cells in the presence of different concentrations of IFO. It could be shown that CYP2B1 -expressing CrFK cells exhibit a much higher sensitivity to IFO, suggesting that the endogenous enzyme KARLE, RENNER, SALMONS, ET AL: CYTOCHROME P450/IFOSFAMIDE MEDIATED NECROSIS is able to activate the drug. Similar results with cyclophosphamide, an isomer of IFO, have been also obtained for breast cancer cells 3 and gliosarcoma cells. 2 The activated drug led not only to cytotoxic effects in the CYP2B1-expressing cells but also had cytotoxic effects on cells of the same cell type that were grown in the vicinity confirming previous studies. 2, 3, 18, 19 This bystander effect induced by released activated IFO has, in comparison to other systems, the advantage that the action of the activated drug is independent of the cell cycle and of gap junctions. This contrasts to the most commonly used suicide gene / drug system herpes simplex thymidine kinase with acyclovir / ganciclovir. 20, 21 Furthermore, the bystander effect of CYP2B1 -expressing and IFO -activating cells is not only restricted to adherent growing cell types and to a direct cell ± cell contact as previously investigated, 2, 3, 18, 19 but can also be transferred to cells with different characteristics. For example, A20 suspension cells, which were in loose contact with CYP2B1 -expressing CrFK cells, showed a strong growth inhibition in the presence of IFO. At an IFO concentration of 0.5 mM, there was no visible effect on A20 cells cocultured with CrFK wild -type cells but a considerable inhibition of A20 cell growth was observed when they were cocultivated with CYP2B1 -expressing cells (clone C8III -1 ). Thus, there seems to be a clear window between therapeutic response and nonspecific cytotoxicity.
In previous studies, we and others showed that the bystander effect of CYP2B1 -expressing cells together with IFO or cyclophosphamide is mediated by freely diffusible metabolites that can pass through 0.45 -m pores. 4, 22 For an exact quantification of the percentage of the CYP2B1 -expressing cells required in a population to achieve good cell killing of bystander cells, pancreatic tumor cells ( PANC1) were modified to stably express EGFP and co -plated in different ratios with CYP2B1-expressing C8III -1 cells. Unmodified CrFK cells, the parental cells of the C8III -1 clone, were also used in the experiment to ensure that the same amount of cells was always present in a dish at the start of the experiment. The growth inhibition correlated with the percentage of CYP2B1-expressing cells in the population up to a point. If only 25% of the total population was made up of CYP2B1-expressing cells, around 75% of the target pancreatic cells were killed as a result of the bystander effect. Increasing the percentage of CYP2B1 -expressing cells had, however, no further significant effect on the number of pancreatic target cells killed. This suggests that about 25% of the cells are refractile to CYP2B1 -mediated bystander killing, possibly because they are not cycling although other mechanisms cannot be excluded. This result may not necessarily be relevant for the in vivo setting. Other experiments have shown a complete ablation of tumor cells after implantation of about 0.02% CYP2B1 -expressing cells in a tumor model in vivo. 4 This may be due to the three -dimensional tumor structure that encloses the center of prodrug activation completely. 4 Thus, the measurement of the bystander effect in vitro may underestimate the potential of suicidebased cancer gene therapy. However, although suicide gene therapy can have a therapeutic benefit in vitro, 23 ± 25 in animal models 26 and in clinical trials, 23 it has yet to be used to cure a patient with cancer. To achieve cures it will probably be necessary to additionally activate the patient's immune system to detect any residual tumor cells at the site of the primary tumor and to eliminate distant metastases. One way to do this may be to enhance the production and presentation of tumor-specific antigens as a result of massive tumor cell necrosis. 27 Most of the cytostatic drugs, which are used for gene -based and conventional anticancer therapy, cause cell death by initiating apoptosis. 28 For IFO's sister drug cyclophosphamide, both an apoptotic 29, 30 as well as a nonapoptotic mechanism 31 have been proposed. From the understanding of the mechanism of phosphoramide mustard ± induced DNA interstrand links, it would seem most likely that IFO -treated cells undergo apoptosis when faced with their inability to repair their DNA damage. Surprisingly, however, in our studies, annexin V /propidium iodide staining as well as electron microscopy did not reveal any IFO -induced signs of apoptosis. These cells are, however, able to undergo apoptosis when treated with staurosporine. CYP2B1-expressing, IFO -treated, or 4OOH -IFO ± treated cells showed swelling, micronucleisation, vacuolisation, and sometimes a dilated ER. At the end of the death process, the cells burst and release their contents into the surrounding media. Micronucleisation is an indicator of genotoxic stress and reflects the DNA -alkylating activity of the activated IFO. This phenomenon was already reported for cyclophosphamide. 32 Others have shown that soon after exposure to cyclophosphamide cells become arrested at the G2 /Mcheckpoint. 30 This effect could also be seen when A20 suspension cells were grown in the vicinity of CYP2B1-expressing cells in the presence of IFO ( Fig 3) . All these data support the model of cellular DNA modification by activated IFO ( isophosphoramide mustard ) in which the cell tries to correct DNA damage by excision repair. 33 During this repair, the cell is arrested in the G2 /M-phase. However, later on, the cells appear to directly enter necrosis. This may be an effect of the protein -alkylating activity of acrolein, 2, 34 which can interfere with proteins of the caspase cascade thus preventing apoptosis occurring.
Apoptotic cells typically retain their integrity and demonstrate typical morphological characteristics like reduced volume, DNA condensation, and formation of apoptotic bodies. 35 Macrophages and neighboring cells take up the apoptotic cellular rudiments, thereby reducing fix meal, exposure of intracellular antigens and inflammation. Although this mechanism is important to maintain homeostasis and to enable a remodelling of organs during ontogenesis, 36 it is probably disadvantageous for anticancer therapy. The release of cell contents as seen from cells treated with activated IFO may send``signals of danger'' 27 into the surrounding environment and cause infiltration of the tumor with lymphocytes and a general inflammation. 9 Thus, the finding that CYP2B1 activation of IFO causes necrotic cell death can be seen as an important finding for the development of further adjuvant strategies to be used in combination with CYP2B1 /IFObased anticancer therapy approaches. 
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